Abstract:Abstract Metabolic reprogramming is a major mechanism of fueling cancer cell growth and proliferation. However, how tumor metabolism is altered to confer therapeutic resistance is poorly understood. Gene expression profiling of tamoxifen sensitive and resistant breast cancer cells revealed that transition to the resistance was associated with a specific expression reprogramming of genes involved in glucose/energy metabolism, which was accompanied by aberration of specific epigenetic regulators such as the histone methyltransferase NSD2/MMSET/WHSC1. In cell and xenograft tumor models, NSD2 overexpression alone was sufficient to confer tamoxifen resistance. Analysis of clinical specimens indicates that NSD2 was a strong predictive factor for early relapse of tamoxifen therapy. NSD2 wild type, but not its methylase-defective mutant form, coordinately stimulated the expression and enzymatic activity of HK2, TIGAR and G6PD and strongly augmented the pentose phosphate pathway (PPP) production of NADPH for ROS reduction and survival of tamoxifen treated cells and tumors. Further mechanistic studies demonstrated that elevated NSD2 stimulates the metabolic gene expression through H3K36 methylation at the target chromatin. Pharmacological targeting aberrant NSD2 by DZNeP, an S-adenosylhomocysteine (AdoHcy) hydrolase inhibitor, effectively blocked the growth of tamoxifen-resistant tumor. The study reveals a novel mechanism of cancer metabolic reprogramming and suggests targeting the key metabolic re-programmer as a viable option for effective treatment of endocrine resistant tumors. Note: This abstract was not presented at the meeting. Citation Format: June X. Zou, Junjian Wang, Zhijian Duan, Hongwu Chen, Hsing-Jien Kung, Xinbin Chen, Leigh C. Murphy, Alexander Borowsky. Metabolic reprogramming by an epigenetic mechanism in endocrine therapy resistance of breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2433. doi:10.1158/1538-7445.AM2014-2433

S-adenosylhomocysteine (Adohcy)-Dependent Methyltransferase Inhibitor DZNep Overcomes Breast Cancer Tamoxifen Resistance Via Induction of NSD2 Degradation and Suppression of NSD2-driven Redox Homeostasis.

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

Reprogramming Metabolism by Histone Methyltransferase NSD2 Drives Endocrine Resistance Via Coordinated Activation of Pentose Phosphate Pathway Enzymes.

Abstract 2433: Metabolic Reprogramming by an Epigenetic Mechanism in Endocrine Therapy Resistance of Breast Cancer

Histone Methyltransferase NSD2 Mediates the Survival and Invasion of Triple-Negative Breast Cancer Cells Via Stimulating ADAM9-EGFR-AKT Signaling

DZNep Inhibits the Proliferation of Colon Cancer HCT116 Cells by Inducing Senescence and Apoptosis

Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradation

2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K/AKT/mTOR pathway

Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents

Tamoxifen Resistance in Breast Cancer is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

EZH2 Inhibition Sensitizes Tamoxifen‑resistant Breast Cancer Cells Through Cell Cycle Regulation.

Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer

Natural Product Toosendanin Reverses the Resistance of Human Breast Cancer Cells to Adriamycin As a Novel PI3K Inhibitor

Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional Prna Nanoparticles.

Combination Therapy with Epigenetic-Targeted and Chemotherapeutic Drugs Delivered by Nanoparticles to Enhance the Chemotherapy Response and Overcome Resistance by Breast Cancer Stem Cells.

Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy

Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.

Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling

Drug Resistance Reversal by Interventing Cancer Bioenergetics with Spherical Helical Polypeptide-Potented Gene Silencing